Pablo G. Legorreta, CEO and Chairman of the Board of Royalty Pharma plc, filed a Form 4 on November 6, 2026, disclosing the acquisition of 42,209 Class A Ordinary Shares on November 4, 2026, in connection with the settlement of Equity Performance Awards.

Key Highlights

  • Transaction: Legorreta acquired 42,209 Class A Ordinary Shares at a price of $0 on November 4, 2026, coded as an exempt acquisition under Rule 16b-3.
  • Direct ownership following transaction: 1,350,029 Class A Ordinary Shares held directly after the reported transaction.
  • Indirect holdings: Additional Class A Ordinary Shares are held indirectly through multiple vehicles, including 1,040,410 by Legorreta Children 2002 Trust and 901,590 by GST-Exempt Legorreta 2012 Family Trust, among others.
  • Class B shares: The reporting person and family vehicles hold 73,195,660 Class B Ordinary Shares, each exchangeable into one Class A Ordinary Share.
  • Class E shares: 13,356,742 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, exchangeable into Class A Ordinary Shares, are also held and are subject to vesting conditions.
  • Filing note: The form was signed by Sean Weisberg as Attorney-in-Fact for Pablo G. Legorreta on November 6, 2026.

Legorreta's Share Acquisition and Beneficial Ownership at Royalty Pharma

According to the filing, Pablo G. Legorreta, who serves as CEO and Chairman of the Board of Royalty Pharma plc (NASDAQ:RPRX), acquired 42,209 Class A Ordinary Shares on November 4, 2026. The filing describes the acquisition as "the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards," at a price of $0 per share. The transaction code is listed as "A" (acquired).

Following this transaction, the filing reports that Legorreta directly holds 1,350,029 Class A Ordinary Shares. In addition, the filing discloses a range of indirectly held Class A Ordinary Share positions: 1,040,410 shares by the Legorreta Children 2002 Trust; 901,590 by the GST-Exempt Legorreta 2012 Family Trust; 600,000 by the Legorreta 2023 SR Trust; 460,139 by Legorreta Investments LLC; 292,190 by Tata MC 35 Ltd.; 123,310 by IRRA; 118,500 by SEP/IRA; 41,306 by the GST-Exempt Legorreta 2020 Family Trust; 10,000 by Son; 10,000 by Daughter; and 6,930 by Spouse.

The filing's remarks section further discloses that Legorreta and family vehicles controlled by him hold 73,195,660 Class B Ordinary Shares, each exchangeable into one Class A Ordinary Share, and 13,356,742 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, also exchangeable into Class A Ordinary Shares. The filing notes that the Class E Ordinary Shares "are subject to vesting conditions." No derivative securities transactions were reported in Table II.

What Was Disclosed

The filing disclosed an exempt acquisition of 42,209 Class A Ordinary Shares by CEO and Chairman Pablo G. Legorreta on November 4, 2026, through Equity Performance Award settlement at $0, along with a detailed accounting of his direct and indirect beneficial ownership across multiple holding vehicles.